Cities Changing Diabetes
28 March - Novo Nordisk today announces the launch of ‘Cities Changing Diabetes’, an ambitious new partnership programme to fight the urban diabetes challenge. The ‘Cities Changing Diabetes’ programme will first be launched in Mexico City with other cities in North America, Europe and Asia soon to follow. “The global diabetes epidemic is an emergency in slow motion," says Lars Rebien Sørensen, chief executive officer, Novo Nordisk. "While there are many factors fuelling the growth trajectory of diabetes, the most striking contributor is urbanisation and the growth of cities. The ‘Cities Changing Diabetes’ programme is our call to arms for people around the world to work together to tackle this for the long-term."
550 million DKK investment in new purification pilot plant in Denmark
14 March - Novo Nordisk is increasing its drug development capacity by investing 550 million Danish kroner (100 million US dollars) in a new research and development facility in Bagsværd, Denmark. The purification plant will expand the company’s capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs under development. “The new purification pilot plant will significantly increase our capacity for early-phase diabetes projects. It will create up to 35 new jobs over a two-year period in addition to the 100 new employees CMC Supply will hire in Denmark in 2014”, said Jesper Bøving, senior vice president, CMC Supply.
Read the full release
Clinical Trial Transparency
1 March - Novo Nordisk has made it easier for external researchers to get access to clinical trial data. You may read about how we conduct our clinical trials, about volunteering to participate, how we disclose trial information to the public and how researchers can access clinical trial datasets.
Read more about clinical trials.
Diabetes - a global pandemicSee the infographic on diabetes facts and statistics - a global challenge (pdf)
Hypoglyceamia - a challenge
Important safety information
25 October - Novo Novo Nordisk recalls some NovoMix®30 insulin products in European countries
Novo Nordisk is recalling certain batches of its prefilled insulin product NovoMix®30 FlexPen® in Austria, Belgium, Czech Republic, Denmark, France, Germany, Iceland, Luxemburg, Netherlands, Norway and Slovakia. In Ireland and the UK, three batches of NovoMix®30 Penfill® are being recalled. Other countries in the EU might have received the affected batches through parallel distribution.
NovoMix®30 is a product used for the treatment of diabetes.
The challenges of developing a tablet
Video: Senior Vice President of diabetes research Peter Kurtzhals about the challenges of developing a tablet and about the different types of diabetes.
Click here to see the presentation.
Diabetes and the discovery of insulin
Video: Chief Science Officer Mads Krogsgaard Thomsen explains about diabetes, the discovery of insulin, differences in insulin and blood sugar control.
Click here to see the presentation.
Financial statement, Q1 2014
5th International DAWN(TM) Summit
8 April - There's an urgent need to mobilise and involve people with diabetes in partnership efforts to face the challenges of the diabetes pandemic. Read more about the pledge on the DAWNTM summit to work together for the 382 million people living with diabetes around the world.
28 February - Read the stories behind the numbers and learn abouth the people, actions and how it all adds up in Novo Nordisk's reporting.
Novo Nordisk Stories
Team Novo Nordisk racing
16 January - Team Novo Nordisk, the world’s first all-diabetes professional cycling team, starts its second season on 20 January at the Tour de San Luis in Argentina, with four talented new riders and even higher aspirations. Read more about the team’s mission to educate, empower and inspire those affected by diabetes and follow the team results on facebook and twitter.
7 February - Novo Nordisk's annual report for 2013 is now available for download. The report will also be available for print end February.